JP2021531278A5 - - Google Patents
Info
- Publication number
- JP2021531278A5 JP2021531278A5 JP2021502604A JP2021502604A JP2021531278A5 JP 2021531278 A5 JP2021531278 A5 JP 2021531278A5 JP 2021502604 A JP2021502604 A JP 2021502604A JP 2021502604 A JP2021502604 A JP 2021502604A JP 2021531278 A5 JP2021531278 A5 JP 2021531278A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- nucleoside
- modified
- modified oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701317P | 2018-07-20 | 2018-07-20 | |
| US62/701,317 | 2018-07-20 | ||
| PCT/US2019/042561 WO2020018887A1 (en) | 2018-07-20 | 2019-07-19 | Methods for oral delivery of oligonucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021531278A JP2021531278A (ja) | 2021-11-18 |
| JP2021531278A5 true JP2021531278A5 (https=) | 2022-07-26 |
Family
ID=67704556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502604A Pending JP2021531278A (ja) | 2018-07-20 | 2019-07-19 | オリゴヌクレオチドの経口送達のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220098581A1 (https=) |
| EP (1) | EP3824087A1 (https=) |
| JP (1) | JP2021531278A (https=) |
| CN (1) | CN112424356A (https=) |
| TW (1) | TW202019441A (https=) |
| WO (1) | WO2020018887A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282964A1 (en) * | 2022-05-23 | 2023-11-29 | Universitat de Valéncia | Oligonucleotides conjugated to oleic acid and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1120707C (zh) | 1995-11-22 | 2003-09-10 | 约翰斯·霍普金斯大学 | 增强生物分子的细胞摄取的配体 |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| SI2539451T1 (sl) | 2010-02-24 | 2016-04-29 | Arrowhead Research Corporation | Sestavki za ciljano dostavo sirna |
| EP2561102A1 (en) * | 2010-12-02 | 2013-02-27 | Katholieke Universiteit Leuven K.U. Leuven R&D | Irak-related interventions and diagnosis |
| AU2011343664B2 (en) | 2010-12-17 | 2015-10-08 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA |
| WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| US9506030B2 (en) * | 2013-05-01 | 2016-11-29 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| SG10201803157XA (en) * | 2013-05-01 | 2018-05-30 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-122 |
| KR20170033439A (ko) * | 2014-08-07 | 2017-03-24 | 레굴루스 테라퓨틱스 인크 | 대사 장애에 대한 마이크로rna의 표적화 |
-
2019
- 2019-07-19 JP JP2021502604A patent/JP2021531278A/ja active Pending
- 2019-07-19 TW TW108125529A patent/TW202019441A/zh unknown
- 2019-07-19 WO PCT/US2019/042561 patent/WO2020018887A1/en not_active Ceased
- 2019-07-19 EP EP19756448.7A patent/EP3824087A1/en not_active Withdrawn
- 2019-07-19 CN CN201980048096.XA patent/CN112424356A/zh active Pending
- 2019-07-19 US US17/259,366 patent/US20220098581A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7376952B2 (ja) | ｓｉＲＮＡ複合体及びその調製方法と使用 | |
| JP7478210B2 (ja) | 修飾オリゴヌクレオチド及び使用方法 | |
| US11414659B2 (en) | 4'-phosphate analogs and oligonucleotides comprising the same | |
| CN111655849B (zh) | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 | |
| EP2992096B1 (en) | Compounds and methods for enhanced cellular uptake | |
| JP2022507282A5 (https=) | ||
| JP2016518841A5 (https=) | ||
| JP2021074021A5 (https=) | ||
| JP2021522841A5 (https=) | ||
| JP2021502120A5 (https=) | ||
| JP2021072862A5 (https=) | ||
| JP2017514489A5 (https=) | ||
| JP2022501059A5 (https=) | ||
| JP2019503394A5 (https=) | ||
| JP2022535708A (ja) | 核酸、薬物組成物及び複合体ならびに調製方法と使用 | |
| JP2024079716A5 (https=) | ||
| Liczner et al. | Beyond ribose and phosphate: selected nucleic acid modifications for structure–function investigations and therapeutic applications | |
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| JP2017505623A5 (https=) | ||
| JP2019525918A5 (https=) | ||
| JP2021522804A5 (https=) | ||
| TW201446791A (zh) | 用於調節mir-122之微小rna化合物及方法 | |
| TW202334427A (zh) | 單股寡核苷酸 | |
| IL277970B2 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease | |
| JP2022527105A5 (https=) |